OMX Copenhagen 20 Stock OMX COPENHAGEN 20
Add to a list
To use this feature you must be a member
Log inSign up

News of the index components OMX Copenhagen 20

Index

OMXC20

DK0016268840

Real-time Nasdaq Copenhagen 04:22:26 2024-07-10 am EDT 5-day change 1st Jan Change
2,823 PTS +0.11% Intraday chart for OMX Copenhagen 20 -0.10% +23.65%
Jul. 02 Indices: CAC relaxes, Merval soars Our Logo
Jun. 05 Nordic Shares Moved Upward Wednesday; Crayon Group Topped Leaders DJ

News of the index components

Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Danske Bank share buy-back programme: Transactions in week 26
DANSKE
GL
Transactions in connection with share buyback programme
ISS
GL
Genmab A/S - Completion of Share Buy-back Program
GMAB
AQ
Danske Bank A/S : Statement on principal adverse impacts of investment decisions on sustainability factors Danske Bank
DANSKE
PU
Danske Bank A/S revises 2024 net profit upwards. Now expects a net profit in the range of DKK 21-23 billion
DANSKE
AQ
Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU
GMAB
MT
NOVO NORDISK : UBS gives a Neutral rating
NOVO B
ZD
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
GMAB
BU
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
GMAB
GL
Genmab A/S Announces Epcoritamab Receives Positive CHMP Opinion for Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
GMAB
CI
Genmab Closes DKK3.5 Billion Share Buyback Early
GMAB
MT
Completion of Share Buy-back Program
GMAB
GL
Novo Nordisk to Limit Launch of Wegovy in China, Executive Says
NOVO B
MT
Genmab A/S - EPKINLY Approved by U.S. FDA for Patients with Relapsed or Refractory Follicular Lymphoma
GMAB
AQ
BTIG Adjusts Price Target on Genmab to $47 From $46, Maintains Buy Rating
GMAB
MT
Danske Bank A/S : Tax Policy
DANSKE
PU
Danske Bank A/S : List of excluded companies and issuers
DANSKE
PU
NOVO NORDISK : JP Morgan gives a Buy rating
NOVO B
ZD
Tryg A/S will publish Q2 and H1 results 2024 and hosts a conference call on 11 July 2024
TRYG
AQ
Genmab Gets FDA Approval for Follicular Lymphoma Treatment
GMAB
MT
Danske Bank A/S : Scope Ratings Danske rating report June 2024
DANSKE
PU
NOVO NORDISK : Goldman Sachs reiterates its Buy rating
NOVO B
ZD
Genmab Wins US Approval for Follicular Lymphoma Treatment
GMAB
MT
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
GMAB
BU
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
GMAB
GL
Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY
GMAB
CI
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours
NOVO B
MT
2seventy Bio Sells Gene Editing Therapy To Novo Nordisk for Up To $40 Million
NOVO B
DJ
Sector Update: Health Care Stocks Lower in Afternoon Trading
NOVO B
MT
Sector Update: Health Care
NOVO B
MT
Novo Nordisk to Take $816.2 Million Impairment Loss After Stopping Clarion-CKD Trial
NOVO B
MT
Novo Nordisk Halts Late-stage Hypertension, Kidney Disease Treatment Trial; DKK6 Billion Impairment Loss Expected
NOVO B
MT
Novo Nordisk: trial failure and impact on results
NOVO B
CF
Novo Nordisk to Take $816.2 Million Impairment Loss After Stopping Clarion-CKD Trial
NOVO B
MT
Novo Nordisk to Take $816 Million Impairment Charge After Stopping Clarion-CKD Trial
NOVO B
MT
Novo Nordisk makes impairment loss of $816 million in Q2
NOVO B
RE
Novo Nordisk stops the ocedurenone CLARION-CKD trial and recognises impairment loss
NOVO B
GL
New US fill finish facility receives $4.1 billion investment
NOVO B
AQ
Dewpoint Therapeutics Strengthens Collaboration with Novo Nordisk to Accelerate Drug Discovery
NOVO B
AQ
Ambu A/S : obtains FDA clearance for new ureteroscopy endoscopy solution
AMBU B
PU
No results for this search
12345

Rankings

Highest OMX Copenhagen 20 increases
COLOPLAST A/S Stock Coloplast A/S
+2.81%
AP MOLLER MAERSK Stock AP Moller Maersk
+1.16%
DANSKE BANK A/S Stock Danske Bank A/S
+0.94%
ORSTED A/S Stock Orsted A/S
+0.18%
ISS A/S Stock ISS A/S
+0.61%
GENMAB A/S Stock Genmab A/S
+0.16%
PANDORA A/S Stock Pandora A/S
+0.10%

The sharpest declines in OMX Copenhagen 20.
GN STORE NORD A/S Stock GN Store Nord A/S
-0.16%
NOVO NORDISK A/S Stock Novo Nordisk A/S
-0.14%
NOVONESIS A/S Stock Novonesis A/S
-0.33%
See the ranking

% Price Change by Sector

ETF components
Detailed heatmap
  1. Stock Market
  2. Indexes
  3. OMX Copenhagen 20 - Denmark
  4. News OMX Copenhagen 20
  5. News of the index components